Biotechnology company Viventia Bio Inc. filed for an initial public offering Wednesday, seeking to sell up to $86.25 million worth of shares. The company specializes in targeted-protein cancer therapies. Viventia cautioned it has incurred “significant losses” since it was started and such losses are likely to continue. As of June, Viventia had a deficit of $31.3 million. Underwriters include Cowen and Co. and Guggenheim Securities. The company will trade on the Nasdaq stock exchange under the symbol VITA.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News